Implantação de dispositivos de ressincronização e/ou desfibrilhação em doentes com insuficiência cardíaca

• Autor(a) principal: Bonhorst, Daniel
• Data de Publicação: 2019
• Outros Autores: Guerreiro, Sara, Fonseca, Cândida, Cardim, Nuno, Macedo, Filipe, Adragão, Pedro
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/147791
• topic: Heart failure; Hospitalization; Implantable cardiac devices; Mortality; Reduced left ventricular ejection fraction; Resynchronization; Cardiology and Cardiovascular Medicine

Introduction: The aim of this study was to document clinical practice in Portugal regarding the use of electronic cardiac devices in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Methods: The Síncrone study was an observational prospective multicenter registry conducted in 16 centers in Portugal between 2006 and 2014. It included adult patients with a diagnosis of HF, LVEF <35% and indication for implantable cardioverter‐defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) devices, according to the recommendations of the European Society of Cardiology at the beginning of the study. Patients were followed for one year according to the practice of each center. Results: A total of 486 patients were included in the registry, half of whom received an ICD and the other half a CRT pacemaker (CRT‐P) or CRT defibrillator (CRT‐D). Mean age was 65±12 years and the most frequent causes of HF were ischemic (47%) and idiopathic dilated cardiomyopathy (28%). Overall mortality at one year was 3.6% and the hospitalization rate was 11%, significantly higher in patients with CRT‐P/CRT‐D than with ICD (17% vs. 5.6%, p<0.001). Patients who received CRT‐P/CRT‐D experienced significant reductions in QRS duration (160±21 vs. 141±24 ms, p<0.001) as well as improvement in New York Heart Association functional class. Conclusion: The Síncrone study shows that the use of implantable devices in HF with reduced LVEF in Portugal is in accordance with international recommendations and that patients presented functional improvement and reduced one‐year mortality.